MolMed gets US FDA Orphan Drug status for malignant mesothelioma drug (PharmaBiz) MolMed S.p.A announced that the U S Food and Drug Administration has granted Orphan Drug designation for MolMed's investigational new anti-tumour therapeutic drug NGR-hTNF (ARENEGYR) in the treatment of malignant pleural mesothelioma (reference code # 08-2639).
HOME PAGE (The Hindu) Ranbaxy foot-soldiers set to change ‘sales pitch’ Mumbai, Sept. 6 Foot-soldiers of Ranbaxy, some of whom have been with the company for over 20 years, are set to change the “sales pitch” they make when promoting the company’s medicines to doctors across the country. ...
HOME PAGE (The Hindu) Singur talks ‘positive’; to resume today Kolkata, Sept. 5 Talks to end the impasse over land acquisition at Singur for the Tata small car project remained inconclusive on Friday with all parties concerned agreeing to meet at 11 a.m. on Saturday to take the process ...
HOME PAGE (The Hindu) Banks would need Rs 5.68 lakh cr additional capital in next 5 years Maintaining capital-to-risk-weighted assets ratio at 12%. Mumbai, Sept. 4 The banking sector would require additional capital of Rs 5,68,744 crore in the next five years. ...
MemorialMesotheliomaScholarship ... Transmission mesothelioma lawyer TX afterwards mesothelioma lawyer ... mesothelioma meek never memorialmesotheliomascholarshipmesothelioma support mesothelioma attorney mesothelioma ... http://www.maximizingbonds.org/mesothelioma/Missouri-county.html
memorialmesotheliomascholarship Contains many memorialmesotheliomascholarship resources. Click here if you are looking for memorialmesotheliomascholarship http://www.feelingallright.com/memorial-mesothelioma-scholarship.html